Amelioration of Hypophosphatemic Rickets and Osteoporosis With Pamidronate and Growth Hormone in Lowe Syndrome

Journal of the Formosan Medical Association

Volumn 108, Issue 9, 2009, Pages 730-735

  Hou, Jia Woei ^a  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

growth hormone; hypophosphatemic rickets; Lowe syndrome; OCRL1 gene; oculocerebrorenal syndrome; pamidronate

Indexed keywords

ASCORBIC ACID; BICARBONATE; CALCIUM; COLECALCIFEROL; CREATININE; FOLIC ACID; PAMIDRONIC ACID; PHOSPHATE; RECOMBINANT GROWTH HORMONE; VITAMIN B COMPLEX;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; BONE DENSITY; CASE REPORT; CATARACT; CLINICAL FEATURE; CREATININE CLEARANCE; DISEASE COURSE; FACE DYSMORPHIA; FANCONI RENOTUBULAR SYNDROME; GENE SEQUENCE; GROWTH HORMONE DEFICIENCY; HEMATOLOGY; HORMONAL THERAPY; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIC RICKETS; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LABORATORY TEST; LIVER FUNCTION TEST; LOWE SYNDROME; MALE; MICROCEPHALY; MUSCLE HYPOTONIA; OCRL1 GENE; OSTEOPOROSIS; TREATMENT RESPONSE; URINALYSIS; UROGRAPHY; VITAMIN DEFICIENCY;

ADOLESCENT; BONE DENSITY; DIPHOSPHONATES; HUMAN GROWTH HORMONE; HUMANS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; MALE; OCULOCEREBRORENAL SYNDROME; OSTEOPOROSIS; PHOSPHORIC MONOESTER HYDROLASES;

EID: 71549128018     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60397-1     Document Type: Article

References (17)

1. Lowe C.U., Terrey M., and MacLachlan E.A. Organic aciduria, decreased renal ammonia production, hydrophthalmos and mental retardation: a clinical entity. Am J Dis Child 83 (1952) 164-184
2. Richards W., Donnell G.N., Wilson W.A., et al. The oculocerebro-renal syndrome of Lowe. Am J Dis Child 109 (1965) 185-203
3. Loi M. Lowe syndrome. Orphanet J Rare Dis 1 (2006) 16
4. Charnas L.R., Bernardini I., Rader D., et al. Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med 324 (1991) 1318-1325
5. Holtgrewe J.L., and Kalen V. Orthopedic manifestations of the Lowe (oculocerebrorenal) syndrome. J Pediatr Orthop 6 (1986) 165-171
6. Lowe M. Structure and function of the Lowe syndrome protein OCRL1. Traffic 6 (2005) 711-719
7. Constantin A., Laroche M., Moulinier L., et al. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate. Rev Rhum Engl Ed 62 (1995) 493-500
8. Rodan G.A., and Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 97 (1996) 2692-2696
9. Hou J.W. Rapidly Progressive scoliosis after successful treatment for osteopenia in Costello syndrome. Am J Med Genet A 146 (2008) 393-396
10. Weger W., Kotanko P., Weger M., et al. Prevalence and characterization of renal tubular acidosis in patients with osteopenia and osteoporosis and in non-porotic controls. Nephrol Dial Transplant 15 (2000) 975-980
11. Roschinger W., Muntau A.C., Rudolph G., et al. Carrier assessment in families with Lowe oculocerebrorenal syndrome: novel mutations in the OCRL1 gene and correlation of direct DNA diagnosis with ocular examination. Mol Genet Metab 69 (2000) 213-222
12. Addis M., Loi M., Lepiani C., et al. OCRL mutation analysis in Italian patients with Lowe syndrome. Hum Mutat 23 (2005) 524-525
13. Lee S., Glicklich D., and Coco M. Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction. Nephrol Dial Transplant 19 (2004) 2870-2873
14. Markowitz G.S., Appel G.B., Fine P.L., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12 (2001) 1164-1172
15. Smetana S., Michlin A., Rosenman E., et al. Pamidronate-induced nephrotoxic tubular necrosis-a case report. Clin Nephrol 61 (2004) 63-67
16. Sheffer-Babila S., Chandra M., and Speiser P.W. Growth hormone improves growth rate and preserves renal function in Dent disease. J Pediatr Endocrinol Metab 21 (2008) 279-286
17. Valk N.K., Erdtsieck R.J., Algra D., et al. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass. Clin Endocrinol (Oxf) 43 (1995) 317-324